141 related articles for article (PubMed ID: 8840973)
1. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models.
Ko SC; Cheon J; Kao C; Gotoh A; Shirakawa T; Sikes RA; Karsenty G; Chung LW
Cancer Res; 1996 Oct; 56(20):4614-9. PubMed ID: 8840973
[TBL] [Abstract][Full Text] [Related]
2. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model.
Cheon J; Ko SC; Gardner TA; Shirakawa T; Gotoh A; Kao C; Chung LW
Cancer Gene Ther; 1997; 4(6):359-65. PubMed ID: 9408606
[TBL] [Abstract][Full Text] [Related]
3. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy.
Shirakawa T; Ko SC; Gardner TA; Cheon J; Miyamoto T; Gotoh A; Chung LW; Kao C
Cancer Gene Ther; 1998; 5(5):274-80. PubMed ID: 9824046
[TBL] [Abstract][Full Text] [Related]
4. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
6. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
[TBL] [Abstract][Full Text] [Related]
7. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
8. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer.
Kijima T; Osaki T; Nishino K; Kumagai T; Funakoshi T; Goto H; Tachibana I; Tanio Y; Kishimoto T
Cancer Res; 1999 Oct; 59(19):4906-11. PubMed ID: 10519403
[TBL] [Abstract][Full Text] [Related]
9. Human prostate cancer progression models and therapeutic intervention.
Chung LW; Kao C; Sikes RA; Zhau HE
Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
11. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus.
Siders WM; Halloran PJ; Fenton RG
Cancer Gene Ther; 1998; 5(5):281-91. PubMed ID: 9824047
[TBL] [Abstract][Full Text] [Related]
12. Construction of a novel oncolytic adenoviral vector and its biological characteristics.
Zhang M; Zhang X; Han Z; Chen X; Yang L; Sheng Y; Wen J
Oncol Rep; 2013 Feb; 29(2):798-804. PubMed ID: 23165979
[TBL] [Abstract][Full Text] [Related]
13. Pronounced cytostatic activity and bystander effect of a novel series of fluorescent tricyclic acyclovir and ganciclovir derivatives in herpes simplex virus thymidine kinase gene-transduced tumor cell lines.
Balzarini J; Ostrowski T; Goslinski T; De Clercq E; Golankiewicz B
Gene Ther; 2002 Sep; 9(17):1173-82. PubMed ID: 12170381
[TBL] [Abstract][Full Text] [Related]
14. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.
Shirakawa T; Gotoh A; Zhang Z; Kao C; Chung LW; Gardner TA
Urology; 2004 Mar; 63(3):613-8. PubMed ID: 15028478
[TBL] [Abstract][Full Text] [Related]
15. Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors.
Adachi Y; Reynolds PN; Yamamoto M; Grizzle WE; Overturf K; Matsubara S; Muramatsu T; Curiel DT
Cancer Res; 2000 Aug; 60(16):4305-10. PubMed ID: 10969765
[TBL] [Abstract][Full Text] [Related]
16. Suppression of tumor growth and pulmonary metastasis in murine osteosarcoma using gene therapy.
Seto M; Yamazaki T; Sonoda J; Matsumine A; Shinto Y; Uchida A
Oncol Rep; 2002; 9(2):337-40. PubMed ID: 11836603
[TBL] [Abstract][Full Text] [Related]
17. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter.
Vandier D; Rixe O; Besnard F; Kim M; Rikiyama T; Goldsmith M; Brenner M; Gouyette A; Cowan KH
Cancer Gene Ther; 2000 Aug; 7(8):1120-6. PubMed ID: 10975672
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy.
Xie Y; Gilbert JD; Kim JH; Freytag SO
Clin Cancer Res; 1999 Dec; 5(12):4224-32. PubMed ID: 10632364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
